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[Abstract] 
Objectives: Pulmonary vein stenosis is a rare disease with a dismal outcome. Surgical and 
catheter-based interventions on pulmonary veins are associated with recurrent pulmonary vein 
stenosis (PVS) which can progress diffusely through the ‘upstream’ pulmonary veins. Once it 
has diffuse progress, the malignant clinical course will follow without any effective treatment. 
The mechanism has been rarely studied. We used a porcine model of PVS to assess disease 
progression with emphasis on the potential role of endothelial-mesenchymal transition 
(EndMT).    
Methods: One-week-old piglets underwent bilateral pulmonary vein banding in which all 
pulmonary veins have a band around them (Banded, n = 6). Staged operation was applied. A 
left thoracotomy was performed for the left side pulmonary vein banding, followed by the right 
side pulmonary vein bading via a right thoracotomy a week later. The bands tightened the 
pulmonary veins as the piglets grew. Sham operations mimiced the banding procedure without 
a band placed around pulmonary veins (Sham, n = 6). Additional piglets underwent identical 
banding procedure and stent implantation in a single banded right middle pulmonary vein three 
weeks post-banding (Stented, n = 6). Seven weeks post-banding, hemodynamics and upstream 
PV pathology were assessed focusing on EndMT marker expression.  
Results: All Banded piglets developed significant pulmonary hypertension and RV 
hypertrophy 7 weeks after the banding. The upstream pulmonary veins exhibited intimal 
thickening associated with features of EndMT including: increased TGF-β1 and Smad 
expression, loss of endothelial and gain of mesenchymal marker expression. Furthermore, 
intimal cells from upstream pulmonary veins in the banded group demonstrated co-expression 
of endothelial and mesenchymal markers, which indicates that the EndMT process occurs in 
the upstream pulmonary veins under pulmonary vein stenosis. These immunopathological 
changes and a prominent myofibroblast phenotype in the remodeled pulmonary veins were 
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consistently identified in specimens from patients with PVS implying clinical relevance of the 
piglet PVS model. In vitro TGF-β1-stimulated cells isolated from piglet and human pulmonary 
veins, and human umbilical vein endothelial cells all acquired myofibroblast phenotype 
expression supporting the hypothesis in which TGF-β-mediated EndMT could occur in 
pulmonary venous endothelial cells. After stent implantation, although in-stent stenosis was 
developed aggressively in 4 weeks, temporary decompression of a pulmonary vein was 
associated with re-appearance of endothelial marker expression suggesting the potential for 
plasticity in the observed pathologic changes.  
Conclusions: Neonatal pulmonary vein banding in piglets recapitulates critical aspects of 
clinical PVS and highlights a pathologic profile consistent with EndMT - supporting the 
rationale for evaluating therapeutic strategies designed to exploit reversibility of upstream 
pulmonary vein pathology.  
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[Introduction] 
 
3.1 Clinical translation  
Pulmonary vein stenosis (PVS) occurs as either a primary congenital or an acquired 
disease after repair of total anomalous pulmonary venous drainage (TAPVD) [1-3]. The 
outcomes associated with PVS are dismal irrespective of clinical context. Surgical and stent-
based strategies to treat PVS necessarily involve some component of pulmonary vein injury 
and are associated with high rates of recurrent PVS and progression to end-stage disease [4]. 
When recurrent, surgical and catheter-based interventions can treat local PVS at the left atrial-
pulmonary vein junction, however they cannot treat the upstream pulmonary venous disease 
which persists after treatment and dictates the likelihood of survival – with probability of 
survival of less than 20% at one year for patients with diffuse involvement of all four 
pulmonary veins [5, 6]. Repeat surgical interventions are often not feasible and, as a last resort, 
palliative stenting of the pulmonary veins is performed with re-stenosis rates of 46% at 6 
months and 63% at one year – with patient survival of 66% at two years [7].  
A unique characteristic of the clinical syndrome is the potential for progressive and 
diffuse stenosis throughout the pulmonary venous system. Although commonly manifest as a 
local stenosis at the pulmonary vein-left atrial junction, the most malignant form of the disease 
is characterized by diffuse involvement of the ‘upstream’ pulmonary veins extending into the 
lung parenchyma. Because of the diffuse nature of upstream pulmonary vein involvement, 
chemotherapy protocols have been undertaken to treat diffuse PVS – without success [8]. With 
the diffuse upstream lesion, PVS leads to relentless pulmonary hypertension, right heart failure, 
and death. Despite scattered recent reports of catheter-based interventions and surgical 
procedures [9, 10], the overall prognosis is poor [5-7, 11]. Remarkably, the cellular 
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mechanisms and pathophysiology that cause upstream PVS remain incompletely explored and, 
as a result, there is no known medical therapy that ameliorates diffuse PVS disease.  
 
3.2 Endothelial cell injury triggers cellular phenotype transition  
Recently, we have made an observation that cells isolated from specimens acquired 
during surgical repair of TAPVD exhibit loss of an endothelial cell layer and obtained 
proliferation of mesenchymal cellular phenotype cells including myofibroblasts (MyoFB). This 
process resembles endothelial-mesenchymal transition (EndMT), which appears to parallel the 
more commonly described epithelial-mesenchymal transition (EpiMT), and has been 
implicated in fibrogenic diseases and vascular remodeling [12]. 
 
3.3 Epithelial-mesenchymal transition (EpiMT) 
EpiMT is a process in which cells lose their epithelial phenotype and acquire 
characteristic features of mesenchyme [13]. It is a highly orchestrated and regulated process, 
resulting in the loss of epithelial cell adhesion, disruption of tubular basement membrane, and 
enhanced cell migration and invasion [13]. The critical molecular hallmarks of EpiMT include 
repression of E-cadherin, acquisition of a migration-competent, spindle cell phenotype with 
expression of fibroblastic specific protein 1 (FSP-1), and the production of extra-cellular matrix 
comprised principally of collagen I and fibronectin [14]. Three types of EpiMT are known; 
Type 1 EpiMT involves primitive epithelial cells transitioning to motile mesenchymal cells as 
part of gastrulation and during cardiac valve formation [15]. Type 2 EpiMT involves secondary 
epithelial or endothelial transitioning to resident tissue fibroblasts, and can occur in somatic 
organs such as lung, heart, and kidney as an inducible fibrogenic response consequent to 
persistent inflammation [15]. Type 3 EpiMT is epithelial cell transitioning to mesenchymal 
phenotype seen in the metastasis process of the cancer [15]. 
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3.4 Endothelial-mesenchymal transition (EndMT) 
EndMT refers to the analogous process through which endothelial cells lose endothelial 
characteristics and gain expression of mesenchymal, myofibroblast-like characteristics [12]. 
Although less frequently investigated than EpiMT, EndMT is known to occur during normal 
cardiac and vascular development as well as during pathophysiological vascular remodeling 
[15]. EndMT refers to a process whereby endothelial cells respond to an injury stimulus (e.g. 
increased wall stress) by losing endothelial cell markers (e.g. E-Cadherin, CD-31), and gaining 
expression of mesenchymal myofibroblast markers (e.g. α-smooth muscle actin (α-SMA), FSP-
1). During this process, the endothelial cells lose polarity and cell-cell contacts, acquire an 
invasive migratory phenotype, and transition into a spindle shape [12]. Importantly, plasticity 
between EndMT and the reverse process (mesenchymal-endothelial transition), is dynamic and 
can be pushed in either direction, suggesting potential for the reversibility of the pathologic 
changes for an undefined period of time after initiation [15]. We propose that the fibrogenic 
response seen in PVS represents a pulmonary vein-specific form of EndMT.  
 
3.5 TGF-β mediated pathological process 
Transforming growth factor-β (TGF-β) is a known mediator of EndMT in pathologic 
processes and in normal cardiovascular development [12, 15-17]. Inhibition of TGF-β in 
pressure-overloaded rodent models of EndMT is sufficient to block myocardial fibrosis [15, 
18]. Important mediators of TGF-β-induced EndMT include Smad3 and Snail [15]. TGF-β 
levels are increased in the pulmonary vasculature of rats with pulmonary hypertension and 
TGF-β superfamily signaling has been identified as a trigger of pulmonary arterial hypertension 
[19, 20]. The role of TGF-β in pulmonary venous hypertension has been rarely described with 
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only two isolated reports describing increased levels of TGF-β after pulmonary venous injury 
induced by radiofrequency ablation of adult pulmonary veins [21, 22]. 
 
3.6 Study objectives 
In order to investigate the cellular mechanisms associated with PVS, we utilized a 
neonatal piglet model which was previously established by LaBourene et al [23] and 
recapitulates the clinical and pathological PVS with the objective of examining the 
histopathology of upstream PVS to characterize the diffuse fibrogenic response in the 
pulmonary veins, hypothesizing EndMT-like phenotype change is attributed to the disease 
process. Furthermore, we investigate whether pathological reversibility or regression at the 
cellular level is witnessed in the upstream pulmonary veins after treating the PVS with stent 
deployment.  
 
3.7 Hypothesis  
We hypothesize that obstructed pulmonary veins undergo endothelial cell injury and 
trigger TGF-β mediated EndMT-like transformation of their endothelial cell layer as a critical 
early stage in the pathogenesis of PVS – which ultimately leads to progressive fibrogenesis 
characteristic of PV occlusive disease, producing a pathologic cellular phenotype that includes 
loss of endothelial cell properties and gain of MyoFB properties (Figure 1). Blocking the 
conversion of endothelial cells to this pathologic cell type, or stent-based reduction in 
pulmonary venous obstruction may reverse the upstream pulmonary venous disease 
progression.  
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[Methods]  
 
4.1 Research ethics board approval  
The Animal Care Committee at the Hospital for Sick Children approved the animal 
studies in accordance with the Terms of Reference following the Canadian Council on Animal 
Care Guidelines and federal/provincial legislations. Human samples were acquired with 
approval of the Research Ethics Board protocols under the auspices of the Heart Centre 
Biobank Registry (#1000011232, #0020010432). 
 
4.2 Piglet pulmonary vein stenosis model 
 One-week-old Yorkshire piglets (3.9 ± 0.8 kg) underwent staged bilateral pulmonary 
vein banding (Banded, n = 6) or sham operations (Sham, n = 6). After anesthesia and 
intubation, piglets underwent staged operations as previously described [23]. Piglets were 
anesthetized with atropine, ketamine, and isoflurane, intubated and ventilated on a ventilator. 
General anesthesia was maintained with isoflurane (2-3 %), air (70 %), and oxygen (27 %) 
under positive pressure ventilation (20 cm H2O, 30 - 40 breaths/min). Staged operations were 
adopted as previously described [23]. First, the individual banding of left pulmonary veins and 
common lower pulmonary vein was performed via a left 5th intercostal space thoracotomy. 
One week later, the individual banding of the right upper and middle pulmonary veins was 
carried out via a right 4th intercostal space thoracotomy. Bupivacaine (0.5 %) was injected for 
intercostal nerve blocks. A 1/8 inch-wide cotton umbilical tape was fixed around the 
pulmmonary vein with a length equivalent to 1.3 times the pulmonary vein circumference. 5 % 
dextrose lactated Ringer's solution (150 ~ 175 cc), cefazolin (40 mg/kg iv) and procaine 
penicillin G (30,000 units/kg im) were administered. Bupremorphine (0.02 mg/kg, every 8 
hours, 3 days, im) and Meloxicam (0.4 mg/kg, every 24 hours, 3 days, p.o.) were given for pain 
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control. Sham-operated piglets underwent identical banding procedures but the band was not 
left in place. 
 Echocardiography was performed under anesthesia with ketamine and isoflurane before 
banding/sham operation and at 3 and 6 weeks post-procedure. At 7 weeks after bilateral 
banding/sham procedures, the piglets were anesthetised and instrumented to monitor 
hemodynamic parameters using 5 Fr thermodilution catheters (Teleflex, Limerick, PA). 
Systemic blood pressure (SBP), pulmonary arterial pressure (PAP), pulmonary capillary wedge 
pressure (PCWP), right ventricular pressure (RVP), and central venous pressure (CVP). 
Cardiac output (CO), pulmonary vascular resistance: (mean PAP – PCWP) / CO), systemic 
vascular resistance (SVR: (mean SBP – CVP) / CO), and compliance of the pulmonary artery 
(Comp: 1000 × CO / (mean PAP – PCWP)) were measured. Cardiac output was determined by 
injection of 23 ± 1 C ̊ saline (5 cc) into main PA and calculated with cardiac output computer 
(Model 9520A, Edwards Lifesciences, Irvine CA). Subsequently, a median sternotomy was 
performed and left and right ventricular pressures were measured simultaneously by apical 
catheterization. Lung biopsies were taken from each left distal middle lobe. The heart and lungs 
were quickly removed en bloc and dissected on a bed of ice. The upstream pulmonary veins 
were obtained, excluding pulmonary veins within the first 10 mm from banded sites, and 
sectioned for the primary cell culture, fixed in 10 % formalin, or frozen. Hematoxylin and eosin 
(HE) staining was used to show the intimal thickness and pulmonary vein morphology. Intimal 
thickness was assessed by measurement of the ratio of intimal to intimal + medial layer 
thickness at eight radial points in each pulmonary vein.  
 
4.3 Stent implantation 
Other six piglets were allotted for stent treatment (Stented, n = 6). Three weeks after 
identical bilateral pulmonary vein banding with the banded group, the stented group underwent 
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placement of bare-metal stents (Driver, Medtronic Inc., Minneapolis, MN) into the right middle 
pulmonary vein via femoral vein catheterization with 8Fr sheaths under fluoroscopic and 
intracardiac echocardiographic guidance (8 Fr AcuNav catheter, Biosense Webster, Diamond 
Bar, CA). After atrial septum puncture with a pediatric transseptal needle (COOK, 
Bloomington, IN), using a 6F RunWay WRP guide catheter (Boston Scientific Corp., Natick, 
MA), a bare-metal stent (3.5 or 4.0 mm in diameter) was deployed into the banding site of right 
middle pulmonary vein. Acetylsalicylic acid 10 mg/kg/day (Tanta pharmaceuticals Inc., ON, 
Canada) and clopidogrel 2.5 mg/kg/day (Teva Canada, ON, Canada) were given orally until 
the end point of the study. Seven weeks post-banding, invasive hemodynamics were measured 
and tissues were excised as described above. The stented portions of the pulmonary veins were 
excised and cross-sectioned at 3 points within the stent (proximal, middle and distal) cut by an 
Isomet slow-speed saw (Buehler, Lake Bluff, IL) and tungsten carbide knife. The percentage 
of in-stent re-stenosis was quantified using Image J software (National Institutes of Health, 
Bethesda, MD) according to the following formula: 100 × (ICM-LA) / ICM (ICM = inner area 
of the internal circumference of the media, LA = inner area of internal circumference of the 
intima) [24-26]. 
 
4.4 Human tissue 
Pulmonary vein specimens were obtained from three patients with PVS. One patient 
had recurrent PVS after TAPVD repair (at two days of age) followed by reoperation for 
progressive PVS (at three months of age) and subsequent death. Autopsy specimens were 
stained for immunofluorescence as described below (Figure 2C-G). A second patient, with a 
diagnosis of tetralogy of Fallot and PVS, underwent intracardiac repair and pulmonary vein 
stent implantation at the age of 17 months. However, subsequent in-stent re-stenosis and severe 
pulmonary hypertension resulted in death at age 20 months.  At autopsy, Movat pentachrome 
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staining was performed to assess the PV morphology in one patient (Figure 2A). A third patient, 
diagnosed with hypoplastic left heart syndrome, had recurrent refractory PVS after heart 
transplant at the age of five months and died at the age of nine months. Elastic Masson’s 
trichrome staining of the pulmonary veins was employed at autopsy (Figure 2B). 
Control human pulmonary vein tissues were obtained from a heart transplant donor who 
was two months old and did not have pulmonary vascular disease, which were analysed using 
the same immunofluorescence protocols (Figure 2H-L) and cultured for High-Content Imaging 
(HCI) analysis. 
 
4.5 RV cellular size, myocardial fibrosis and collagen deposition 
Transmural blocks of the right ventricular myocardium from banded and sham groups 
were fixed in 10% formalin and sectioned and stained with HE and Masson’s trichrome stains 
[27]. All the slides were stained at the same time under identical conditions. The RV free 
walls were separated into three areas (Epicardium, myocardium and endocardium). 
Myocardial section was examined by 40 X objective lens and 10 X eyepiece. Total 60 
randomly selected high power fields (HPF, 400 X) per piglet were used for analysis of 
cellular size and cardiac fibrosis. The diameters of cells from each area were determined by 
measuring the distance across the cell at its narrowest plane across the nucleus (Image J). The 
area of myocardial collagen content for each high power field slide was quantified 
(Photoshop CS4) and the area of blue stain was expressed as a percentage of the entire slide. 
The mean of these measurements from three RV layers was calculated. 
 
4.6 Immunofluorescence 
Paraffin-embedded tissue slides were deparaffinized in xylene and rehydrated in 
ethanol. Antigens were remasked with Sodium Citrate Buffer (Dako, Glostrup, Denmark), then 
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immersed in blocking buffer for 40 minutes and incubated with primary antibodies CD31 
(1:100, Abcam, Cambridge, UK), fibronectin (1:200, BD Transduction Laboratories, Franklin 
Lakes, NJ), vascular endothelial-cadherin (VE-cadherin, 1:100, Thermo Fisher Scientific, 
Waltham, MA), alpha-smooth muscle actin (α-SMA, 1:100, Santa Cruz Biotechnology), 
fibroblastic specific protein 1 (FSP-1)/S100A4 (1:100, Millipore), von Willebrand factor VIII 
(vWF, 1:100, Dako) and TGF-β1 (1:100, Abcam) for 2 hours at room temperature, followed 
by the secondary anti-rabbit antibody (1:1000) and anti-mouse FITC (1:100) for 1 hour at room 
temperature. Slides were visualized using Quorum WaveFX-X1 Spinning Disc Confocal 
System (Quorum Technologies, ON, Canada) and Volocity software (PerkinElmer Inc., 
Waltham, MA).  
 
4.7 Protein extraction and western-blot analysis 
 Upstream PV samples from piglets were homogenized in lysis buffer, centrifuged for 
20 min at 13,400 g at 4°C and the supernatants were collected. Protein extracts were quantified 
with Bradford protein assay (Bio-Rad, Hercules, CA). Samples were separated on 10 % 
polyacrylamide gels, transferred to nitrocellulose membranes, and blocked with 5 % skimmed 
milk for one hour. The membranes were probed with CD31 (1:1000), VE-cadherin (1:1000), 
α-SMA (1:1000), TGF-β1 (1:1000), Smad4 (1:500, Abcam) and GAPDH (1:6000, Sigma-
Aldrich, St. Louis, MO). Blots were then incubated with goat anti-mouse IgG-HRP (1:10,000) 
and goat anti-rabbit IgG-HRP (1:5000) secondary antibodies. Membranes were developed with 
ECL substrate (Santa Cruz Biotechnology). Densitometry was analyzed using Quantity One 
and Image Lab analysis software (Bio Rad Laboratories, Hercules, CA). GAPDH was used to 
verify all protein loads and normalize data. 
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4.8 Isolation and cell culture 
Pulmonary vein samples from piglets and human were minced and washed with 
phosphate-buffered saline (PBS). Cell isolation was performed with 5% trypsin and 1 mg/ml 
type II collagenase in 20% glucose PBS at 37°C (pH 7.4). After isolation, the cells were 
cultured in Iscove’s modified Dulbecco medium (Life Technologies, Carlsbad, CA) with 
antibiotics and incubated in 5 % CO2 at 37 °C. Human umbilical vein endothelial cells 
(HUVEC) were purchased from ATCC (Manassas, VA) and cultured in the same manner.  
Cultured human PV cells from a heart transplant donor, banded piglet PV cells, and 
HUVECs were treated with 5ng/ml recombinant human Transforming Growth Factor-Beta1 
(TGF-β1) (R&D systems Inc., Minneapolis, MN) for 48 hours to mimic the EndMT process 
[12]. Cells that were not treated with TGF-β1 served as controls. 96- or 384-well plates were 
used to grow, stain, image and analyze cells in a semi-automated fashion using High-Content 
Imaging to increase reliability and statistical significance. Immunofluorescence was performed 
using the fibronectin (1:100) and α-SMA (1:100) antibodies. Nuclei were stained with Hoechst 
(1x). Samples were imaged in a Cellomics VTI automated high-content imager and analysed 
using a combination of Image J and custom written software. Integrated fluorescent intensity 
per cell were counted. For all three cell types, more than 400 cells per condition were tested, 
in triplicates. 
 
4.9 Statistical analysis 
Continuous variables were expressed as mean ± standard error of the mean. The 
unpaired t test was used for comparisons in echocardiography data, western-blot analysis data, 
and intimal thickness data between banded and sham groups. Multiple group comparisons 
between sham, banded, and stented groups were compared by one-way ANOVA followed by 
Tukey's post hoc test. HCI statistics were generated using custom scripts written for the R 
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software package and represented as Winsorized means (5 % tails) and p-values were 
calculated by Mann-Whitney test. 
 
 
[Results] 
 
5.1 Human PVS induces a decrease in endothelial and gain of mesenchymal markers in 
the hyperplastic intima 
Histology staining in PV tissues from patients with progressive PVS demonstrated 
fibromuscular hyperplasia in the intima of the pulmonary veins (Figure 2A) and arterialization 
of a pulmonary vein with marked luminal narrowing (Figure 2B). In the patient with obstructed 
TAPVD, Immunofluorescence showed that the pulmonary veins had greater expression of 
fibronectin and α-SMA, diminished expression of CD31 and vWF, and exhibited stronger 
TGF-β1 expression compared with control human pulmonary veins (Figure 2C-L). The loss of 
endothelial markers and gain of mesenchymal markers indicated a possible phenotypic 
conversion of the endothelium into reparative myofibroblasts, consistent with EndMT process. 
 
5.2 Banding of the pulmonary veins reproduces functional consequences of human PVS 
in a porcine model 
Echocardiography data in sham and banded groups were taken at 3 and 6 weeks after 
operation (n = 6 in each group). Pressure gradient over pulmonary vein in banded group 
elevates significantly at the 3 weeks after banding while right ventricular pressure demonstrates 
mild elevation. Six weeks post-banding, echocardiography demonstrated the pulmonary vein 
gradient increased progressively to 11.50 ± 4.76 mmHg (vs. 3.40 ± 3.36 mmHg in the sham 
group, p < 0.01) and accordingly elevated RV systolic pressure in the banded group (52.17 ± 
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18.03 mmHg vs 23.25 ± 3.30 mmHg in the sham group). There are no significant differences 
in other parameters (Table 1). 
Consistent with PVS in human patients, banding of porcine pulmonary veins induced 
changes in hemodynamics. At seven weeks post-procedure, banded piglets had equivalent 
central venous pressure (4.83 ± 4.08 vs. 1.83 ± 1.47 mmHg), higher pulmonary capillary wedge 
pressure (11.33 ± 3.07 vs. 5.33 ± 2.14 mmHg, p = 0.01), systolic right ventricular pressure 
(38.8 ± 8.77 vs. 19.50 ± 2.43 mmHg, p < 0.01), and mean pulmonary arterial pressure (34.3 ± 
8.89 vs. 12.0 ± 2.37 mmHg, p < 0.01) compared with sham animals. The ratio of mean 
pulmonary arterial pressure to mean systemic blood pressure was higher in banded piglets than 
in sham piglets (0.65 ± 0.18 vs. 0.23 ± 0.02 mmHg, p < 0.01). Cardiac output was not different 
between groups (0.14 ± 0.02 vs. 0.15 ± 0.02 L/min/kg, p = 0.25). Banded piglets had higher 
pulmonary vascular resistance (7.54 ± 2.91 vs. 1.44 ± 0.24 mmHg/l/min, p < 0.01), and lower 
pulmonary vascular compliance (1.81 ± 1.34 vs. 7.20 ± 1.57 ml/mmHg, p < 0.01) (Table 2). 
Banded piglets had more RV hypertrophy compared to sham animals as assessed by 
the ratio of right ventricular weight to left ventricular plus ventricular septal weight (RV / LV 
+ septum: 0.65 ± 0.10 vs. 0.35 ± 0.02, p = 0.01). Histological and morphological analysis 
demonstrated RV hypertrophy manifested with a greater average diameter of RV myocytes in 
the banded group (16.67 ± 1.12 vs. 13.95 ± 1.80 µm, P = 0.02) and a higher percentage of 
collagen deposition in the RV of the banded group compared with the sham group (7.96 ± 2.66 
vs. 2.88 ± 1.02 %, p = 0.01) (Figure 3). 
Stent implantation in a single pulmonary vein at three weeks after banding did not 
improve overall hemodynamics. There were no significant differences in any hemodynamic 
parameters when comparing stented and non-stented banded piglets seven weeks post-banding. 
(Central venous pressure; 4.83 ± 4.08 vs. 5.50 ± 2.88 mmHg, p = 0.58, pulmonary capillary 
wedge pressure; 11.33 ± 3.07 vs. 14.67 ± 3.67 mmHg, p = 0.12, systolic right ventricular 
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pressure; 38.8 ± 8.77 vs. 44.67 ± 9.69 mmHg, p = 0.30, mean pulmonary arterial pressure; 34.3 
± 8.89 vs. 37.7 ± 7.31 mmHg, p = 0.49, the ratio of mean pulmonary arterial pressure to mean 
systemic blood pressure; 0.65 ± 0.18 vs. 0.79 ± 0.15 mmHg p = 0.17, cardiac output index; 
0.14 ± 0.02 vs. 0.14 ± 0.03 L/min/kg, p = 0.78, pulmonary vascular resistance; 7.54 ± 2.91 vs. 
7.64 ± 2.58 mmHg/l/min, p = 0.61, and pulmonary vascular compliance; 1.81 ± 1.34 vs. 1.26 
± 0.53 ml/mmHg, p = 0.38, between the banded and stented group). The ratio of right 
ventricular weight to left ventricular plus ventricular septal weight did not differ between the 
banded and stented group. (RV / LV + septum: 0.65 ± 0.10 vs. 0.73 ± 0.15, p = 0.17) (Table 
2). 
 
5.3 Banding of porcine pulmonary veins mimics the intimal morphological changes 
observed in human PVS 
Morphological changes in upstream pulmonary veins from the banded piglets were 
analyzed. These veins had greater intimal thickness compared to sham piglets (15.48 ± 8.76 vs. 
3.07 ± 1.04 %, p < 0.01) (Figure 2M-P). Small pulmonary veins in the distal lung parenchyma 
had greater intimal hyperplasia and luminal stenosis compared to sham piglets (Figure 2Q-R). 
Next, we assessed fibroproliferative changes in upstream banded pulmonary veins by 
immunofluorescence and Western blotting. Compared to sham piglets, the upstream pulmonary 
veins in banded piglets had greater expression of the mesenchymal markers fibronectin and 
FSP-1, and myofibroblast marker α-SMA (Figure 4A-F). Western-blot analysis confirmed 
greater expression of α-SMA in upstream banded pulmonary veins compared to sham piglets 
(α-SMA / GAPDH; 1.03 ± 0.26 vs. 1.38 ± 0.26, p-value = 0.028, Figure 4). 
To test whether fibroproliferative changes affected distribution and expression of 
endothelial markers, we immunostained for CD31, vWF, and VE-cadherin. Expression of all 
endothelial markers decreased in upstream banded pulmonary veins (Figure 4G-L), similar to 
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the changes seen in human PVS samples (Figure 2C-L). Western blotting confirmed lower 
expression of the endothelial markers CD31 and VE-cadherin in banded piglet pulmonary veins 
(CD31 / GAPDH; 0.20 ± 0.08 vs. 0.10 ± 0.07, p = 0.031 and VE-cadherin / GAPDH; 2.42 ± 
0.58 vs. 1.72 ± 0.36, p = 0.017) (Figure 4). Double immunostaining of CD31 and α-SMA 
(Figure 5A-F) was performed to investigate the pathologic process associated with transition 
of individual cells with co-expression of endothelial and mesenchymal markers. Imaging 
revealed intermittent intimal cells co-expressing endothelial and mesenchymal markers in 
banded pulmonary vein cells (transitional cell phenotype) (Figure 5G). Co-expression of these 
markers was never observed in pulmonary veins of sham animals.  
 
5.4 Intimal hyperplasia following pulmonary vein banding is associated with pro-fibrotic 
signalling events 
One of major drivers of EndMT is TGF-β-mediated signalling events that involve 
phosphorylation and subsequent nuclear translocation of Smad [28, 29]. Expression of TGF-
β1 in the pulmonary veins was greater in banded piglets compared to sham piglets (Figure 5H-
I). Quantitatively, Western-blot analysis demonstrated increased expression of TGF-β1 and 
Smad 4 in banded upstream PVs compared to sham PVs (TGF-β1 / GAPDH; 1.15 ± 0.32 vs. 
1.73 ± 0.34, p = 0.01, Smad 4 / GAPDH; 0.50 ± 0.15 vs. 0.76 ± 0.24, p = 0.05 Figure 5). 
 
5.5 Stent implantation partially reverses the changes induced by experimental PVS 
Seven weeks after pulmonary vein banding (four weeks after stent implantation), 
upstream pulmonary veins in the stented piglets demonstrated greater expression of TGF-β1 in 
comparison to sham animals but less expression than banded animals (by subjective evaluation 
of immunofluorescence images), suggesting partial down regulation of TGF-β expression, and 
partial reappearance of CD31 and vWF (endothelial marker) expression with enhanced and 
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localized fibronectin and α-SMA (mesenchymal and myofibroblast markers) expression in the 
intima (Figure 6A-J), consistent with partial reversal or delayed progression of the 
immunohistochemical features of EndMT. A cell layer expressing endothelial markers in the 
stent group formed jagged notches rather than a smooth even layer implicating acquisition of 
invasive phenotype. In stent re-stenosis reduced the luminal diameter within the stent by 43 ± 
28 % four weeks after stent implantation in the porcine model (Figure 6K). 
 
5.6 Three types of cultured cells are prone to experimentally induced EndMT 
All three cultured cell types (banded piglet PV cells, human control PV cells, and 
HUVECs) demonstrated increased expression of the myofibroblast markers fibronectin and α-
SMA after TGF-β1 exposure (integrated fluorescent intensity per cell, fibronectin; piglet cells; 
1008 ± 89 vs. 1044 ± 120 a.u., p < 0.05, human cells; 3918  ± 111 vs. 4836  ± 123 a.u., p  <  
0.05, HUVECs; 1418 ± 102 vs. 2160 ± 176 a.u., p < 0.01, α-SMA; piglet cells; 3679 ± 167 vs. 
5935 ± 400 a.u., p < 0.01, HUVECs; 1882 ± 160 vs. 2072 ± 189 a.u., p < 0.05. Figure 7). The 
increase in the MyoFB markers for the human and piglet PV samples illustrates that stimulation 
with TGF-β1 are able to recapitulate the pathologic process observed in the clinical condition 
and our whole animal model. Similarly, the increase in fibronectin and α-SMA in the HUVEC 
cells shows that, on a cellular level, stimulation with TGF-β1 are able to emulate EndMT with 
pure endothelial cells. This is consistent with our histology data that shows the gain of MyoFB 
cell markers with pulmonary vein banding and localization of this process to the endothelial 
layer of the vein.  After all, the increase in the myofibroblast markers suggests that stimulation 
with TGF-β1 recapitulates the pathologic process observed in the in vivo animal model.   
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[Discussion] 
 
We previously investigated a piglet model of progressive PVS which revealed increased 
pulmonary vascular resistance and degradation of the internal elastic lamina of the pulmonary 
veins [23]. The precise molecular pathways leading to the pulmonary venous fibrogenic 
response, however, remain unknown. Our piglet model mimics the critical aspects of clinical 
PVS, including myocardial change, hemodynamic deterioration, and pathological manifest in 
the upstream pulmonary veins. Examination of upstream pulmonary veins implicates 
involvement of EndMT in the pathologic process demonstrating loss of endothelial marker 
expression and gain of mesenchymal marker expression in the intima. Other data suggesting a 
role for EndMT in the pathology include the finding of co-expression of endothelial and 
mesenchymal markers in the pulmonary vein intimal cells of banded piglets - albeit at low 
frequency. The presence of such co-expression has been cited as supportive evidence for the 
intermediate stage of EndMT [15, 30, 31].  
TGF-β - mediated EndMT has been observed to participate in several other fibrogenic 
diseases where vascular remodelling is a critical component of the pathologic process [12, 15, 
32, 33]. In the current study, increased TGF-β and Smad 4 expression were also noted in the 
obstructed PVs from piglets. TGF-β is a well-known mediator of EndMT during cardiovascular 
development [12, 15-17]. Increased gene expression of TGF-β isoforms is associated with 
myocardial fibrosis in mice with pressure overload induced by aortic banding [34] and 
inhibition of TGF-β signaling in pressure-overloaded animal models of EndMT is sufficient to 
block myocardial fibrosis [15, 18]. In rat models of pulmonary hypertension, TGF-β levels are 
increased in the pulmonary vasculature and TGF-β signalling is identified as a trigger of 
pulmonary arterial hypertension [19, 20]. Smad is a downstream mediator in the TGF-β 
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signaling pathways with Smad 4, a common mediator interacting with receptor regulated 
Smads which, in turn, is associated with EndMT [32, 35-37]. These data are consistent with a 
model in which regulated TGF-β signaling in the pulmonary vein endothelium, likely resulting 
from abnormal hemodynamic shear stress, promotes EndMT, leading to the generation and 
proliferation of synthetic myofibroblasts within the pulmonary vein wall. 
Our animal model induced the development of progressively severe right ventricular 
hypertrophy and pulmonary hypertension consistent with the clinical course seen in patients 
with severe PVS. The pulmonary veins of the affected piglets exhibited increased TGF-β 
expression, loss of endothelial markers and gain of mesenchymal markers consistent with the 
findings in the human PV samples derived from patients with fatal PVS. Our in vitro studies 
demonstrated that TGF-β-treated cells (human, piglet PV cells, and HUVECs) exhibited a 
similar pattern of mesenchymal/myofibroblast marker expression (fibronectin and α-SMA) that 
was evident in the piglet PVS model and implicates that EndMT-like process occurs in the 
local endothelium. Taken together, these results suggest that this piglet PVS model is consistent 
with the clinical, pathological and cellular changes found in patients with end stage progressive 
PVS. 
Whereas local inflammation at banding site may have a role in diffuse PVS, these data 
suggest that upstream pulmonary vein endothelial injury is associated with elaboration of TGF-
β, Smad signalling events, and proliferation of myofibroblasts in the pulmonary vein wall. 
Local inflammation from the banding material does, however, represent a limitation of our 
model. We have attempted to mitigate this limitation by examining the pulmonary veins 
“upstream” pulmonary veins at locations which were 10 - 40 mm away from banding site. We 
believe this distance is beyond the range of local inflammation. Although difficult to precisely 
identify the geometric extent of the local inflammatory effect, the examined upstream areas 
appeared on gross inspection to be free of obvious induration. Furthermore, our histologic 
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examination was consistent with human samples in which there were no implanted foreign 
bodies to create PVS. 
Although our data were consistent with a role for EndMT in the observed pulmonary 
venous pathology, other mechanisms alone or in combination with EndMT may account for 
the fibrogenic response in the upstream pulmonary veins. The increased number of 
myofibroblasts may be derived from proliferation of local resident mesenchymal cells [38] or 
originate from circulating progenitor cells [39]. 
Proliferation of resident fibroblasts 
Local resident fibroblasts have been hypothesized to be the main source of 
myofibroblasts in wound healing and tissue repair [40, 41]. In addition, migration and 
proliferation of smooth muscle cells and fibroblasts/myofibroblasts have been observed in 
studies of local tissue injury [42, 43]. Traditionally, stimulation and proliferation of resident 
fibroblasts was thought to be the sole origin of fibroproliferative disease [44]. However, more 
recent evidence suggests that contributions to a vascular fibroproliferative response can be the 
consequence of other processes including circulating bone marrow derived fibroblasts and 
endothelial-to-mesenchymal transition (EndMT) [12, 15].  
Bone marrow derived progenitor cells 
Alternatively, circulating bone marrow-derived mesenchymal progenitor cells are 
known to play an important role in tissue remodelling and fibrosis [45] and may contribute to 
the observed pulmonary venous pathology. In a model of hypoxia-induced pulmonary 
hypertension, Frid et al. demonstrated that remodelling of the pulmonary arteries required 
recruitment of circulating mesenchymal precursors [46]. The role of bone marrow derived 
progenitor cells in PVS is not well defined. In a model of pressure-overload induced myocardial 
fibrosis, evaluation of the origin of active fibroblasts demonstrated that a minority was derived 
from bone marrow precursors (~15%) and the remainder was derived from EndMT [15]. 
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Although bone marrow derived progenitor cells are likely to be involved to some extent in PVS, 
there is abundant evidence that EndMT can be demonstrated in ex-vivo models (e.g. without 
circulating bone marrow derived progenitor cells) [16]. In vitro PV cell stimulation with TGF-
β in the current study also revealed increased myofibroblast marker expression which suggests 
myofibroblast proliferation can occur in the local endothelium. 
Thus, the complexity of in vivo histopathologic processes is likely to involve multiple 
mechanisms and proliferation of resident fibroblasts and/or recruitment of circulating 
progenitor cells may make substantial contributions to the observed pulmonary vein pathology 
in our model. However, given the observed substantial evidence of EndMT markers and TGF 
beta signaling pathway markers, EndMT is considered to be the culprit in the pathogenesis of 
PVS. 
The use of high-content imaging in the present study demonstrates that TGF-β induces 
a myofibroblast phenotype in human and piglet pulmonary veins and in HUVECs. We propose 
that this cell-based assay, suitable for high-throughput screening, emulates a critical element 
in the genesis of PVS and could be used to evaluate libraries of compounds for their capacity 
to inhibit this process. This would advance the objective of developing therapeutic agents 
designed to target TGF-β1-mediated transformation and the disease-relevant molecular 
pathways leading to PVS.  
Very few studies have evaluated the effect of stent implantation in obstructed 
pulmonary veins and these studies tend to focus on in-stent re-stenosis rather than the 
histopathology of the upstream pulmonary veins. Indeed, we noted significant in-stent re-
stenosis within four weeks of stent placement, which is consistent with the limited efficacy of 
stents to treat pediatric PVS [7]. Furukawa et al. evaluated the effectiveness of drug-eluting 
stents in pig pulmonary veins [26]. However, in their study the stents were deployed in 
unobstructed pulmonary veins. In contrast, our report is the first to evaluate the efficacy of 
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stents in a model of progressive PVS. Future studies to test the efficacy of stents may be more 
informative if performed in the setting of an experimental model of PVS. The piglet model is 
a ‘high yield’ model because there is ample opportunity to study mechanisms of upstream PVS, 
in-stent restenosis, and right ventricular failure due to pressure overload, although those are 
beyond the scope of the current study. 
Despite the temporary reduction of obstruction, upstream pulmonary veins responded 
to stent implantation with jagged layer of cells expressing some return of endothelial markers, 
diminished TGF-β expression and enhanced mesenchymal markers suggesting the potential for 
plasticity in the observed pathophysiologic process. Reversal of EndMT is known to occur, i.e. 
mesenchymal-endothelial transition [47]. Stenting appears to have initiated some reversal of 
the process possibly due to temporary relief of local pulmonary venous hypertension. Rapid 
in-stent re-stenosis, however, likely limited the efficacy of the intervention. We need to study 
more time points after stent implantation to better characterize the alterations in pulmonary 
venous pathology associated with relief of obstruction. The origin of the cells expressing 
endothelial markers after stenting is unclear and these cells could arise from mesenchymal-
endothelial transition, circulating endothelial progenitor cells [48, 49] or enhanced re-
expression from native endothelial cells. Although the mechanism is unclear, the potential for 
reversibility of the pathologic process warrants further investigation to develop novel adjuvant 
therapies designed to promote reversal of the process in concert with local surgical and stent-
based decompression of pulmonary vein stenosis. 
 
  
[Conclusion] 
The piglet pulmonary vein stenosis model described herein recapitulates critical aspects 
of clinical PVS, including the myocardial alterations, hemodynamic sequelae, and the 
27 
 
histopathologic features in the affected pulmonary veins. Examination of the cellular response 
in upstream pulmonary veins reveals upregulation of TGF-β expression, loss of endothelial 
markers and gain of mesenchymal markers among constituent lesional cells, implicating 
EndMT in the pathologic process. Evidence of reappearance of endothelial marker expression 
with enhanced and localized mesenchymal and myofibroblast markers in the upstream 
pulmonary veins after stenting suggests potential regression of the pathologic process and an 
element of reversibility at the cellular level highlighting new avenues of investigation.  
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[Figure legends] 
 
Figure 1: Scheme of hypothesis for PV fibrosis 
PV endothelial injury triggers TGF-β mediated EndMT and consequently myofibroblast 
proliferation leads to upstream PV fibrosis. 
 
Figure 2: Histology and immunofluorescence staining in human and piglet pulmonary veins 
A: human pulmonary vein histology from a PVS patient; Movat pentachrome staining showed 
fibromuscular hyperplasia. B: human PVS lung tissue; elastic trichrome staining demonstrated 
marked pulmonary vein intimal hyperplasia (arterialization) with luminal narrowing. C-G: 
Pulmonary veins from a TAPVD patient with PVS. (400× magnification) Compared with the 
control histology; H-L: control pulmonary veins from a heart transplant donor without PVS, 
endothelial markers (CD 31 and vWF: D, E) were decreased and expression of TGF-β1 (C) and 
mesenchymal markers (fibronectin and α-SMA; F, G) were increased in the TAPVD patient, 
consistent with the piglet study. M-P: HE staining of upstream pulmonary veins in the piglet model. 
M-N: sham group; O-P: banded group. Banded PVs had increased intimal thickness (red arrows 
in P). intimal thickness as percentage of intimal + medial layer thickness was greater in banded 
pulmonary veins. *: p < 0.05 Q-R: representative microvascular changes in the lung. Q: lung tissue 
in the sham group had thin walled pulmonary veins. R: lung tissue in the banded group had intimal 
hyperplasia in pulmonary veins. TAPVD: total anomalous pulmonary venous drainage; vWF: Von 
Willebrand factor; α-SMA: alpha smooth muscle actin. 
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Figure 3: RV myocyte fiber size and collagen deposition 
Left panels; HE staining of RV muscle. Black arrows showed myocyte fiber thickness. Right 
panels; Trichrome staining of RV muscles. Banded group had thicker RV myocyte fiber size and 
much more collagen deposition (blue stained) in RV tissue. 
 
Figure 4: Representative gain of mesenchymal and decrease of endothelial markers in 
immunofluorescent staining of upstream pulmonary veins of the piglet PVS model 
A-C, G-I: upstream pulmonary veins in the sham group; D-F, J-L: upstream pulmonary veins in 
the banded group; Banded pulmonary veins exhibited greater expression of mesenchymal markers 
(fibronectin, FSP-1, and α-SMA, A-F: 400× magnification) and less expression of endothelial 
markers (CD31, vWF and VE-cadherin, G-L: 400× magnification) compared to sham pulmonary 
veins. The banded upstream PV demonstrated increased expression of α-SMA and decreased 
expression of CD31 and VE-cadherin in Western-blot analysis. *: p < 0.05 FSP-1: fibroblast 
specific protein 1, α-SMA: alpha smooth muscle actin, VE-cad: vascular endothelial cadherin.  
 
Figure 5: Co-expression of endothelial and mesenchymal markers confirming the presence of the 
EndMT transitional cell phenotype 
A-C, H: upstream pulmonary veins in the sham group; D-G, I; upstream pulmonary veins in the 
banded group; A-F: Immunofluorescence showed decreased endothelial and increased 
mesenchymal markers in banded PVs; G: In the banded group, intimal cells expressed an 
endothelial marker (CD31 in red) in the outer membrane and a mesenchymal marker (α-SMA in 
green) in the intracellular space, consistent with a EndMT transitional cell. (600× magnification);  
H-I: expression of TGF-β1; Banded pulmonary veins demonstrated greater expression of TGF-β1 
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compared to sham pulmonary veins (400× magnification). Western-blot analysis supported 
increased expression of TGF-β1 and Smad 4 in banded upstream PVs (p = 0.01 and p = 0.049 
respectively). S; Sham, B; Banded. 
 
Figure 6: Representative immunofluorescent staining and HE staining of stented piglet PVs 
A-E: upstream pulmonary veins in the stented group. F-J: upstream pulmonary veins in the banded 
group. Upstream pulmonary veins from stented piglets demonstrated moderately increased TGF-
β1 expression, regained endothelial markers (B, C) and strong expression of mesenchymal markers 
(D, E). K: representative HE staining of a pulmonary veins with stent from a stented piglet 
demonstrated in-stent re-stenosis. Arrow indicates stent fragments inside the pulmonary venous 
wall. (50× magnification)  A graph on the right shows the percentage of in-stent restenosis 4 weeks 
post-stenting in each stent area. Average area percentage of in-stent stenosis was 43.46 ± 27.85 %.  
 
Figure 7: Induction of EndMT in vitro  
High content imaging of cultured piglet pulmonary vein cells and HUVECs. 
A, C; control banded piglet PV cells. B, D; banded piglet PV cells treated with TGF-β1 (5 ng/ml, 
48 hours). E, G; control HUVECs. F, H; HUVECs treated with TGF-β1 (5 ng/ml, 48 hours). The 
cells treated with TGF-β1 showed an increase in the myofibroblast markers; fibronectin and α-
SMA capturing the EndMT transitional process (p < 0.05 versus control).
 [Figures] 
 
Figure 1: Scheme of hypothesis for PV fibrosis 
 
 
 
 
 
 
 
 Figure 2: Histology and immunofluorescence staining in human and piglet pulmonary veins 
 
 
 
Figure 3: RV myocyte fiber size and collagen deposition 
 
 Figure 4: Representative gain of mesenchymal and decrease of endothelial markers in 
immunofluorescent staining of upstream pulmonary veins of the piglet PVS model 
 
 
 
 
 
 
 
 Figure 5: Co-expression of endothelial and mesenchymal markers confirming the presence of the 
EndMT transitional cell phenotype 
 
 
 
 
 
 
 
 Figure 6: Representative immunofluorescent staining and HE staining of stented piglet PVs 
 
 
 
Figure 7: Induction of EndMT in vitro 
 
 [Tables] 
 
Table 1: Echocardiographic data 
 
 
HR: heart rate, PVG: pulmonary vein gradient, RVSP: right ventricular systolic pressure, RVEDD: 
right ventricular end-diastolic dimension, IVSD: interventricular septal width at diastole, LVEDD: 
left right ventricular end-diastolic dimension, LVSF: left ventricular shortening fraction. 
 
 
 
 Table 2: Hemodynamic data  
 
 
 BW; body weight, HR; heart rate, BSA; body surface area, ABP; arterial blood pressure, CVP; 
central venous pressure, RVP; right ventricular pressure, PAP; pulmonary arterial pressure, 
PCWP; pulmonary capillary wedge pressure, CO; cardiac output, CI; cardiac index, PVR; 
pulmonary vascular resistance, SVR: systemic vascular resistance, Comp; pulmonary vascular 
compliance, RVEDP; right ventricular end-diastolic pressure, LVEDP; left ventricular end-
diastolic pressure, RV/LV+S; ratio of weight of right ventricle against left ventricular and septal 
weight  * p-value in comparison between banded and sham groups  ̾ p-value in a comparison 
between banded and stent groups 
 
